Last updated: September 27, 2026
Ampicillin/sulbactam is a mature, off-patent injectable antibiotic sold primarily to hospitals and government purchasers. The market has low brand pricing power, limited standalone revenue disclosure, and recurring exposure to manufacturing disruptions. Its commercial value is driven by hospital formulary status, generic supply reliability, contract pricing, and antimicrobial-resistance trends rather than exclusivity.
The combination is marketed in the United States as generic ampicillin sodium/sulbactam sodium for injection and was historically sold under the brand name Unasyn. The FDA-approved product is administered intravenously or intramuscularly for infections caused by susceptible organisms, including intra-abdominal, skin and skin-structure, and gynecologic infections.[1]
What is the FDA regulatory status of ampicillin/sulbactam?
Ampicillin/sulbactam is an FDA-approved generic injectable antibiotic with no remaining regulatory exclusivity.
| Regulatory item |
Status |
| Active ingredients |
Ampicillin sodium and sulbactam sodium |
| Dosage form |
Powder for solution for intravenous or intramuscular injection |
| Original brand |
Unasyn |
| Original sponsor |
Pfizer predecessor companies |
| Original FDA approval |
1980s |
| U.S. regulatory pathway |
Abbreviated New Drug Application, or ANDA, for generic products |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
None identified |
| Pediatric exclusivity |
None currently relevant |
| FDA exclusivity |
No active market exclusivity identified |
| Primary customer base |
Hospitals, health systems, government purchasers, and group purchasing organizations |
The original Unasyn approval was submitted under NDA 050608. FDA labeling identifies the product as an injectable combination of a beta-lactam antibiotic and a beta-lactamase inhibitor.[1]
When does ampicillin/sulbactam lose exclusivity?
Ampicillin/sulbactam lost meaningful exclusivity decades ago. Its commercial protection was based on historical composition, formulation, and regulatory rights associated with the original Unasyn product. Those rights no longer prevent generic competition.
No commercially relevant patent barrier remains for the core combination in the United States. The market is therefore governed by ANDA competition, manufacturing capacity, procurement contracts, and hospital demand.
Patent and exclusivity timeline
| Period |
Event |
Commercial effect |
| 1980s |
FDA approval of Unasyn |
Originator commercialization begins |
| 1990s |
Core patent and regulatory protection mature |
Generic development becomes possible |
| Late 1990s to 2000s |
Generic injectable competition expands |
Brand pricing power declines |
| 2010s |
Product becomes a hospital generic |
Supply reliability becomes more important than patent protection |
| 2020s |
Shortage and procurement volatility affect availability |
Suppliers with dependable sterile capacity gain value |
Exact historical patent families are less important to current market access than the absence of active blocking rights. The original patents do not provide a current basis for delaying generic entry.
What patents protect ampicillin/sulbactam today?
No active U.S. patent is known to protect the basic ampicillin/sulbactam injectable combination as a commercial product.
The potential IP categories are limited to:
- Historical composition patents covering the combination.
- Manufacturing and sterile-fill process claims.
- Packaging or container-closure claims.
- Narrow formulation claims involving concentration, stability, or reconstitution.
- Use claims for particular infections or dosing populations.
These categories do not recreate the market exclusivity of the original product. Manufacturing patents may affect a particular supplier but generally do not prevent other companies from marketing the same active ingredients through separate processes.
What formulations are protected by ampicillin/sulbactam patents?
The commercially relevant dosage form is a sterile powder that is reconstituted before intravenous or intramuscular administration. Generic products are supplied in multiple vial strengths, commonly expressed as total ampicillin/sulbactam content:
| Common presentation |
Ampicillin component |
Sulbactam component |
| 1.5 g vial |
1 g |
0.5 g |
| 3 g vial |
2 g |
1 g |
The standard 2:1 ampicillin-to-sulbactam ratio is central to product identity. Formulation differentiation is limited because the product must meet injectable sterility, potency, stability, and reconstitution requirements.
Any supplier-specific formulation or process patent would have narrow commercial scope unless it materially improved shelf life, reduced manufacturing cost, or solved a shortage-related capacity constraint.
How many patents cover ampicillin/sulbactam?
The active commercial combination has no meaningful active U.S. patent estate comparable to a protected branded drug. Historical patent documents may remain visible in patent databases, but expired patents do not create a current barrier to ANDA approval or generic launch.
The practical IP risk is low for:
- Core active ingredients.
- The 2:1 combination ratio.
- Standard injectable presentations.
- Conventional hospital indications.
The practical IP risk is higher, but still generally limited, for:
- Supplier-specific manufacturing processes.
- Novel delivery systems.
- Extended-stability products.
- Fixed combinations involving other active ingredients.
- New beta-lactamase inhibitor combinations that are not ampicillin/sulbactam.
What is the Orange Book status of ampicillin/sulbactam?
The original Unasyn product is an old injectable product with no current exclusivity that would prevent approved generic competition. FDA Orange Book status for older discontinued or legacy brand products can vary by listing status and marketing activity, but the commercial market is clearly genericized.[2]
The key Orange Book implications are:
- No active brand exclusivity is controlling generic supply.
- ANDA applicants do not face a current core patent barrier.
- Paragraph IV litigation is not a central market feature.
- Generic approval depends mainly on pharmaceutical equivalence, bioequivalence where applicable, sterility, chemistry and manufacturing controls, and facility compliance.
Which companies are challenging ampicillin/sulbactam exclusivity?
No significant current Paragraph IV challenge is required to compete with ampicillin/sulbactam because the original product is already off patent.
Generic competition has historically included large injectable manufacturers and specialized hospital-drug suppliers. The supplier group can change as companies enter, exit, transfer facilities, or face FDA manufacturing actions. Examples of companies that have marketed or supplied hospital injectable antibiotics include:
- Hikma Pharmaceuticals.
- Sandoz.
- Fresenius Kabi.
- Pfizer, including legacy Hospira operations.
- Eugia Pharma Specialities.
- WG Critical Care and related institutional suppliers.
- Other ANDA holders and contract manufacturers.
The relevant competitive question is not which company has defeated a patent challenge. It is which companies maintain qualified sterile manufacturing capacity and reliable distribution.
What patent litigation affects ampicillin/sulbactam?
No major current U.S. patent litigation is central to the commercial market for standard ampicillin/sulbactam injection.
The litigation profile differs from newer branded antibiotics:
| Litigation issue |
Current significance |
| Core composition patent |
Low; historical rights expired |
| Method-of-use patent |
Low for standard labeled indications |
| Formulation patent |
Possible in narrow supplier-specific disputes |
| Paragraph IV litigation |
Not a major current market factor |
| Manufacturing patent |
Potentially relevant to individual suppliers |
| FDA facility litigation or enforcement |
More commercially relevant than patent litigation |
| Contract and procurement disputes |
Relevant in hospital tenders and shortages |
A supplier’s market position can be affected more quickly by a warning letter, product recall, sterile-facility shutdown, or shortage allocation than by a patent injunction.
What generic entry risks exist for ampicillin/sulbactam?
Generic entry risk is high because the product is already genericized. For existing suppliers, the principal risk is additional ANDA competition and price erosion. For hospitals, the risk is supply interruption rather than lack of legal market access.
Commercial risks for manufacturers
- Low average selling prices.
- Hospital and government purchasing pressure.
- Group purchasing organization discounts.
- Limited differentiation between products.
- High fixed costs for sterile injectable manufacturing.
- Regulatory risk at aging facilities.
- Dependence on qualified active pharmaceutical ingredient suppliers.
- Inventory constraints during antibiotic shortages.
The combination may remain commercially attractive when supply is constrained because hospitals cannot rapidly replace it across all indications. That benefit is episodic. It does not establish durable pricing power.
Supply-chain risks
Sterile injectables are vulnerable to:
- Vial and stopper shortages.
- API interruptions.
- Batch failures.
- Facility maintenance shutdowns.
- Long FDA remediation periods.
- Demand surges during respiratory or intra-abdominal infection seasons.
- Substitution pressure from other beta-lactam/beta-lactamase inhibitor products.
The American Society of Health-System Pharmacists and FDA shortage databases have periodically reported availability concerns involving injectable antibiotics, although shortage status changes by product, supplier, and presentation.[3,4]
How does ampicillin/sulbactam compare with competing antibiotics?
Ampicillin/sulbactam competes with both older generic agents and newer protected products.
| Product |
Commercial status |
Main competitive relationship |
| Ampicillin/sulbactam |
Mature generic injectable |
Low-cost broad-spectrum hospital therapy |
| Piperacillin/tazobactam |
Mature generic injectable |
Broader gram-negative and antipseudomonal coverage |
| Ceftriaxone plus metronidazole |
Generic combination strategy |
Alternative for selected intra-abdominal infections |
| Amoxicillin/clavulanate |
Generic oral and injectable forms in some markets |
Step-down or outpatient alternative |
| Meropenem |
Generic injectable |
Escalation therapy for resistant gram-negative infections |
| Sulbactam/durlobactam |
Branded product, Xacduro |
Targeted therapy for susceptible Acinetobacter baumannii-calcoaceticus complex infections |
| Cefiderocol |
Branded or limited-competition product depending on market |
Resistant gram-negative coverage |
Ampicillin/sulbactam does not provide antipseudomonal coverage and is not interchangeable with piperacillin/tazobactam or meropenem. Its value depends on pathogen susceptibility and the infection site.
Sulbactam/durlobactam is not a simple replacement. It was approved in 2023 for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex.[5] It competes for some hospital antibiotic budgets but addresses a more specialized resistance segment.
What is the financial trajectory for ampicillin/sulbactam?
The financial trajectory is mature, low-growth, and supply-sensitive. Public companies generally do not report ampicillin/sulbactam revenue as a separate line item. The product is usually included within broader hospital injectable, generic, or anti-infective portfolios.
| Financial driver |
Direction |
Effect |
| Unit demand |
Stable to modestly variable |
Supported by hospital use and stewardship protocols |
| Unit price |
Downward over long term |
Caused by generic competition and procurement discounts |
| Revenue growth |
Limited |
No exclusivity or major new indication |
| Gross margin |
Variable |
Improved during shortages; pressured during competitive periods |
| Manufacturing cost |
Structurally high |
Sterile production and quality requirements |
| Revenue volatility |
Moderate |
Driven by shortages, tenders, and supply interruptions |
| Investment case |
Capacity and reliability driven |
More dependent on operations than IP |
A supplier can generate attractive temporary returns during a shortage, but sustained growth requires one or more of the following:
- Lower-cost sterile manufacturing.
- Reliable API sourcing.
- Contract wins with hospitals or government buyers.
- A differentiated ready-to-use presentation.
- Better inventory availability than competitors.
- Portfolio cross-selling with other injectable anti-infectives.
The product is unlikely to support premium branded pricing without a differentiated delivery system or a separate regulatory strategy.
What manufacturing and IP barriers affect the market?
Manufacturing is the principal barrier to competition. Ampicillin/sulbactam is chemically old but operationally demanding because it is an injectable sterile product.
Key barriers include:
- Validated aseptic processing.
- Sterility assurance.
- Container-closure integrity.
- Stability through distribution.
- Controlled reconstitution performance.
- Compliance with current good manufacturing practices.
- Availability of high-quality beta-lactam API.
- Segregated handling of sensitizing beta-lactam compounds.
- FDA inspection readiness.
Beta-lactam manufacturing can require dedicated or carefully segregated facilities because cross-contamination presents patient-safety and regulatory risks. Those requirements reduce the number of dependable suppliers even when the drug has no patent protection.
What geographic coverage does ampicillin/sulbactam have?
Ampicillin/sulbactam is marketed in multiple regions, but product names, approved indications, vial sizes, suppliers, and regulatory status vary.
The strongest commercial presence is in hospital markets where:
- Injectable generic antibiotics are routinely purchased.
- Combination therapy is used for intra-abdominal and polymicrobial infections.
- National procurement systems emphasize low acquisition cost.
- Hospitals maintain broad empiric antibiotic formularies.
U.S. revenue is exposed to FDA-approved supplier capacity and hospital contracting. European and emerging-market revenue is more influenced by tender systems, local manufacturing, import approvals, and government reimbursement. China and India have substantial antibiotic manufacturing capacity, but market access depends on local registration, procurement rules, and antimicrobial stewardship restrictions.
What licensing deals affect ampicillin/sulbactam?
No major current licensing transaction is required to commercialize the standard generic combination in the United States. The original branded rights are historical and do not create an active licensing moat.
Potential commercial agreements typically involve:
- Contract manufacturing.
- API supply.
- Regional distribution.
- Hospital purchasing contracts.
- Government tenders.
- Portfolio acquisitions involving injectable products.
A licensing deal would have value primarily if it secures manufacturing capacity, regulatory approvals, or geographic distribution. It would not normally transfer meaningful exclusivity for the base product.
What is the outlook for ampicillin/sulbactam?
The outlook is stable in clinical use but weak in standalone pricing growth.
Demand should remain supported by:
- Continued hospital use for susceptible polymicrobial infections.
- Need for lower-cost empiric therapy.
- Antimicrobial stewardship programs that favor narrower therapy where appropriate.
- Periodic shortages of competing injectable antibiotics.
Growth is constrained by:
- Generic substitution.
- Low reimbursement differentiation.
- Antibiotic stewardship.
- Resistance limiting use in some pathogens.
- Competition from piperacillin/tazobactam, ceftriaxone-based regimens, and carbapenems.
- Lack of patent or exclusivity protection.
The most credible upside is operational rather than scientific. Suppliers with resilient sterile capacity, strong FDA compliance, and dependable hospital distribution can outperform despite a flat underlying market.
Key Takeaways
- Ampicillin/sulbactam is a mature, off-patent hospital injectable antibiotic.
- The core combination has no meaningful current U.S. patent barrier.
- FDA exclusivity has expired, and Paragraph IV litigation is not a major current issue.
- Orange Book relevance is limited to legacy brand and generic listing status.
- Revenue is generally not disclosed separately by manufacturers.
- Pricing is controlled by generic competition, hospital tenders, and group purchasing organizations.
- Sterile manufacturing, API supply, and FDA compliance are more important than patent ownership.
- Shortages can temporarily improve supplier economics but do not create durable market exclusivity.
- Sulbactam/durlobactam competes in resistant Acinetobacter infections but is not a full substitute.
- The long-term financial profile is stable volume, low price growth, and episodic supply-driven volatility.
FAQs about ampicillin/sulbactam patents and market economics
Is Unasyn still protected by patents?
No meaningful core patent protection remains for the original ampicillin/sulbactam injectable combination. Generic products compete in the market.
Is ampicillin/sulbactam subject to a Paragraph IV challenge?
Paragraph IV litigation is not a central current issue because the original product has been genericized for many years and no active core patent barrier controls market entry.
Can a generic manufacturer obtain premium pricing for ampicillin/sulbactam?
Only temporarily. Premium pricing generally requires a shortage, superior supply reliability, a differentiated presentation, or a favorable hospital contract.
Does sulbactam/durlobactam replace ampicillin/sulbactam?
No. Sulbactam/durlobactam is targeted mainly at susceptible Acinetobacter baumannii-calcoaceticus complex infections. Ampicillin/sulbactam has broader historical use in selected polymicrobial and community-associated hospital infections.
What is the main investment risk in ampicillin/sulbactam?
The main risk is sterile-injectable supply disruption combined with low pricing power. Manufacturing failures, API interruptions, recalls, and hospital contract losses can affect revenue more than patent events.
References
-
U.S. Food and Drug Administration. (n.d.). Unasyn: Ampicillin sodium and sulbactam sodium injection prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
American Society of Health-System Pharmacists. (n.d.). Drug shortages database. ASHP.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages. FDA Drug Shortages Database.
-
U.S. Food and Drug Administration. (2023). FDA approves new antibacterial drug for hospital-acquired bacterial pneumonia. FDA.
